Using cerebrospinal fluid biomarkers to diagnose Alzheimer’s disease: an Australian perspective

Using cerebrospinal fluid biomarkers to diagnose Alzheimer’s disease: an Australian perspective

Cerebrospinal fluid (CSF) biomarkers are currently the only clinically validated biofluid diagnostic test for Alzheimer’s Disease (AD) available in Australia. Testing of CSF biomarkers via lumbar puncture (LP), including quantification of amyloid-β peptide, total tau protein, and phosphorylated tau,...

Full description

Saved in:
Bibliographic Details
Main Authors: Dhamidhu Eratne, Steven Collins, Peter J. Nestor, Dimity Pond, Dennis Velakoulis, Mark Yates, Colin L. Masters
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Psychiatry
Subjects:
Alzheimer’s disease
dementia
diagnosis
CSF biomarkers
amyloid
tau
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1488494/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2024.1488494/full

Similar Items